Real‐world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Communications"
DOI: 10.1002/cac2.12150
Abstract: Dear Editor, Despite the introduction of novel front-line therapies including rituximab plus high-dose cytarabine followed by consolidative autologous stem cell transplantation (ASCT) and salvage therapy with bendamustine, lenalidomide or bortezomib, mantle cell lymphoma (MCL) is… read more here.
Keywords: ibrutinib therapy; outcomes ibrutinib; mantle cell; retrospective analysis ... See more keywords
Incidence of invasive fungal infections in patients with hematological malignancies receiving ibrutinib therapy in south-east Austria.
Sign Up to like & getrecommendations! Published in 2022 at "Medical mycology"
DOI: 10.1093/mmy/myac061
Abstract: Since the broad implementation of ibrutinib therapy, an increasing number of studies have been reporting on invasive fungal infections (IFI) associated with ibrutinib administration. We conducted a retrospective cohort study in three hospitals in south-east… read more here.
Keywords: south east; invasive fungal; therapy; east austria ... See more keywords
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort
Sign Up to like & getrecommendations! Published in 2018 at "Haematologica"
DOI: 10.3324/haematol.2018.198820
Abstract: Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia : 30-month follow up of the Swedish compassionate use cohort read more here.
Keywords: real world; term real; world results; long term ... See more keywords
Arrhythmia Patterns in Patients on Ibrutinib
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Cardiovascular Medicine"
DOI: 10.3389/fcvm.2021.792310
Abstract: Introduction: Ibrutinib, a Bruton's tyrosine kinase inhibitor (TKI) used primarily in the treatment of hematologic malignancies, has been associated with increased incidence of atrial fibrillation (AF), with limited data on its association with other tachyarrhythmias.… read more here.
Keywords: ibrutinib therapy; patients ibrutinib; burden patients; arrhythmia patterns ... See more keywords